Physician profile
Paul M Taupeka
NPI 1356364061
$8,125.29
in general payments reported to CMS, 2019-2025
18 companies · $923 in 2025
The $923 reported for 2025 was more than what 78% of Neuro-Ophthalmology providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,398 · 2020: $474 · 2021: $760 · 2022: $1,577 · 2023: $1,061 · 2024: $932 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,916.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $4,262.13 | 2019-2025 | Amo Phaco Needle, Tecnis Iol, One Series Ultra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $819.54 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $815.48 | 2022-2025 | Iolmaster 700, Clarus |
| Bausch & Lomb Americas INC. | $645.91 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Alcon Vision LLC | $467.00 | 2022-2024 | Hydrus Microstent |
| Harrow Eye, LLC | $323.26 | 2024 | Natacyn, Verkazia, Tobradex St |
| Carl Zeiss Meditec, INC. | $137.05 | 2020 | |
| Nova Eye, INC. | $97.12 | 2024 | |
| Amgen INC. | $95.09 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $92.37 | 2020-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $91.18 | 2019 | |
| Alexion Pharmaceuticals, INC. | $89.59 | 2021-2022 | |
| Allergan, INC. | $84.85 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $30.77 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $23.08 | 2023 | Cequa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.74 | 2023 | Alphagan P, Lumigan |
| Aerie Pharmaceuticals, INC. | $18.11 | 2019 | |
| Tandem Diabetes Care, INC. | $10.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Taupeka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.